Literature DB >> 28444740

Chronic lymphocytic leukaemia genomics and the precision medicine era.

Hussein Ghamlouch1,2,3,4, Florence Nguyen-Khac5, Olivier A Bernard1,2,3,4.   

Abstract

Massive genomic analyses have underscored the diversity of chronic lymphocytic leukaemia (CLL) between patients. Genetic heterogeneity of tumour clones within a patient may fuel tumour evolution. Several recurrently deregulated intra-cellular pathways are candidates for targeted therapies that are very promising and are dramatically changing clinical patients' perspectives. In this review we present an overview of the genetic and epigenetic features of CLL and their clinical and biological implications.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic lymphocytic leukaemia; mutations; targeted therapy; tumour evolution

Mesh：

Substances：

Year:  2017        PMID： 28444740     DOI： 10.1111/bjh.14719

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  7 in total

Review 1.  Mechanism of Human Telomerase Reverse Transcriptase (hTERT) Regulation and Clinical Impacts in Leukemia.

Authors:  Mot Yee Yik; Adam Azlan; Yaashini Rajasegaran; Aliaa Rosli; Narazah Mohd Yusoff; Emmanuel Jairaj Moses
Journal:  Genes (Basel)       Date:  2021-07-30       Impact factor: 4.096

2.  Proteomics and metabolomics identify molecular mechanisms of aging potentially predisposing for chronic lymphocytic leukemia.

Authors:  Rupert L Mayer; Josef D Schwarzmeier; Marlene C Gerner; Andrea Bileck; Johanna C Mader; Samuel M Meier-Menches; Samuel M Gerner; Klaus G Schmetterer; Tobias Pukrop; Albrecht Reichle; Astrid Slany; Christopher Gerner
Journal:  Mol Cell Proteomics       Date:  2017-12-01       Impact factor: 5.911

3.  The Conformational State of the BTK Substrate PLCγ Contributes to Ibrutinib Resistance.

Authors:  Raji E Joseph; Jacques Lowe; D Bruce Fulton; John R Engen; Thomas E Wales; Amy H Andreotti
Journal:  J Mol Biol       Date:  2021-12-23       Impact factor: 5.469

Review 4.  Chronic Lymphocytic Leukemia B-Cell Normal Cellular Counterpart: Clues From a Functional Perspective.

Authors:  Walaa Darwiche; Brigitte Gubler; Jean-Pierre Marolleau; Hussein Ghamlouch
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

5.  Biological and metabolic effects of IACS-010759, an OxPhos inhibitor, on chronic lymphocytic leukemia cells.

Authors:  Hima V Vangapandu; Brandon Alston; Joshua Morse; Mary L Ayres; William G Wierda; Michael J Keating; Joseph R Marszalek; Varsha Gandhi
Journal:  Oncotarget       Date:  2018-05-18

6.  The Impact of Chlorambucil and Valproic Acid on Cell Viability, Apoptosis and Expression of p21, HDM2, BCL2 and MCL1 Genes in Chronic Lymphocytic Leukemia.

Authors:  Katarzyna Lipska; Agata Filip; Anna Gumieniczek
Journal:  Cells       Date:  2021-05-02       Impact factor: 6.600

Review 7.  A glitch in the snitch: the role of linker histone H1 in shaping the epigenome in normal and diseased cells.

Authors:  Ankita Saha; Yamini Dalal
Journal:  Open Biol       Date:  2021-08-04       Impact factor: 6.411
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.